arrow
L

Leo I. Gordon

northwestern university feinberg school of medicine
H指数:91
被引数:4.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Five-year survival outcomes of lisocabtagene maraleucel in R/R LBCL from the TRANSCEND NHL 001 study

lisocabtagene maraleucel在TRANSCEND NHL 001研究中复发/难治性LBCL的五年生存结局

Blood
IF23.1
2026-06-050
OAAI
Outcomes of Bispecific Antibodies After CAR T-Cell Failure for Large B-cell Lymphoma- Results from the ABC Consortium

大B细胞淋巴瘤在CAR T细胞治疗失败后使用双特异性抗体的疗效——ABC Consortium研究的结果

2025-10-240
OAAI
B-Cell Lymphomas 3.2025 Featured Updates to the NCCN Guidelines

B细胞淋巴瘤 3.2025 NCCN指南特色更新

2025-10-010
PRE
Nivolumab in Combination with R-CHOP for Treatment-Naïve Diffuse Large B-Cell Lymphoma: An Evaluation of Safety and Efficacy

纳武利尤单抗联合R-CHOP方案治疗初治弥漫性大B细胞淋巴瘤:安全性与有效性的评估

2025-07-280
OAAI
Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study

lisocabtagene maraleucel用于不适合HSCT的R/R LBCL患者的治疗:PILOT研究2期最终结果

2025-05-050
OA
Encapsulation and Delivery of the Kinase Inhibitor PIK-75 by Organic Core High-Density Lipoprotein-Like Nanoparticles Targeting Scavenger Receptor Class B Type 1
2024-12-170
PRE
Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis

CAR T细胞疗法治疗转化型滤泡性淋巴瘤的临床结局:一项美国多中心真实世界分析

BLOOD
IF23.1
2024-11-050
PRE
Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy
2024-05-285
OAAI
Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy
2024-05-166
OAAI
Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study

CAR T细胞治疗后继发性中枢神经系统淋巴瘤患者的结局: 一项多中心队列研究

2023-11-0911
OAAI
B-Cell Lymphomas, Version 6.2023 Featured Updates to the NCCN Guidelines

B细胞淋巴瘤,6.2023版更新了NCCN指南

2023-11-0126
OA